We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Advanced Drug Development a Reality with UK's Most Powerful Nuclear Magnetic Resonance Facility

By LabMedica International staff writers
Posted on 30 Nov 2010
UK researchers are gaining new insights into vital high tech engineering materials and novel pharmaceuticals due to the creation of the UK's most powerful nuclear magnetic resonance (NMR) device for solids now sited in a national research facility.

The new UK 850 MHz Solid-State NMR Facility at the University of Warwick's (UK) Center for Magnetic Resonance was launched in the University's Millburn House on October 28, 2010. More...
It is a national facility open to a large range of researchers across the United Kingdom and has been made possible by the award of a GBP 3.7 million grant from the Engineering and Physical Sciences Research Council (EPSRC; Swindon, Wiltshire, UK) and the Biotechnology and Biological Sciences Research Council (BBSRC; Swindon, Wiltshire, UK).

The new facility was formally launched by David Delpy, the chief executive of EPSRC at a special event, which was attended by researchers from all the main facility partners (Universities of Warwick, Cambridge, Durham, Nottingham, Glasgow, and St. Andrews). David Delpy said, "The EPSRC are pleased to have supported the UK's internationally leading research for over 15 years. NMR spectroscopy is a vital analytical tool science. It is a powerful technique that can provide detailed information on the topology, dynamics, and three-dimensional structure of molecules in solution and the solid state.”

Prof. Mark Smith, deputy vice-chancellor of the University of Warwick, said, "This facility provides a significant leap in the capability available to the UK's NMR spectroscopy researchers that allows us to compete with the very best in the world. This was possible through the coordinated efforts of a wide range of researchers and funders and is a model of such a partnership for developing such facilities for the UK in the future. It is certain to provide us with new insights into everything from potential new pharmaceuticals to innovate materials for the next generation of catalytic convertors.”

Related Links:
University of Warwick
UK Engineering and Physical Sciences Research Council
UK Biotechnology and Biological Sciences Research Council


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.